

1 **COVID-19 and first trimester spontaneous abortion: a case-control study of 225 pregnant patients**

2 Stefano Cosma Ph.D.<sup>1\*</sup>, Andrea Carosso M.D.<sup>1\*</sup>, Jessica Cusato Ph.D.<sup>2</sup>, Fulvio Borella M.D.<sup>1</sup>, Marco Carosso  
3 M.D.<sup>1</sup>, Marialuisa Bovetti M.D.<sup>1</sup>, Claudia Filippini Ph.D.<sup>3</sup>, Antonio D'Avolio Ph.D.<sup>4</sup>, Valeria Ghisetti Ph.D.<sup>5</sup>,  
4 Giovanni Di Perri Ph.D.<sup>4</sup> and Chiara Benedetto Ph.D.<sup>1</sup>

5  
6 <sup>1</sup> Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, University of Turin, Via  
7 Ventimiglia 3, 10126, Turin, Italy

8 <sup>2</sup> Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical  
9 Sciences, University of Turin, Corso Svizzera 164, 10149, Turin, Italy

10 <sup>3</sup> Department of Surgical Sciences, City of Health and Science, University of Turin, Corso Dogliotti 14, 10126, Turin,  
11 Italy

12 <sup>4</sup> Unit of Infectious Diseases, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Corso  
13 Svizzera 164, 10149, Turin, Italy.

14 <sup>5</sup> Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Corso Svizzera 164,  
15 10149, Turin, Italy.

16  
17 \*Joint first authors.

18  
19 **Disclosure:** The authors report no conflict of interest

20 **Financial Support:** research university funds

21  
22 **Correspondence address:**

23 Stefano Cosma, Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, University  
24 of Turin, Via Ventimiglia 3, 10126, Turin, Italy

25 Email: stefano.cosma@unito.it

26 Tel: +39 3356643972/+39 011 3131711

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 **ABSTRACT**

43

44 **Background**

45 Evidence for the impact of COVID-19 during the second and the third trimester of pregnancy is limited to a relatively  
46 small series, while data on the first trimester are scant. With this study we evaluated COVID-19 infection as a risk  
47 factor for spontaneous abortion in first trimester of pregnancy.

48

49 **Methods**

50 Between February 22 and May 21, 2020, we conducted a case-control study at S. Anna Hospital, Turin, among first  
51 trimester pregnant women, paired for last menstruation. The cumulative incidence of COVID-19 was compared  
52 between women with spontaneous abortion (case group, n=100) and those with ongoing pregnancy (control group,  
53 n=125). Current or past infection was determined by detection of SARS-CoV-2 from nasopharyngeal swab and SARS-  
54 CoV-2 IgG/IgM antibodies in blood sample. Patient demographics, COVID-19-related symptoms, and the main risk  
55 factors for abortion were collected.

56

57 **Findings**

58 Twenty-three (10.2%) of the 225 women tested positive for COVID-19 infection. There was no difference in the  
59 cumulative incidence of COVID-19 between the cases (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73).  
60 Logistic regression analysis confirmed that COVID-19 was not an independent predictor of abortion (1.28 confidence  
61 interval 0.53-3.08).

62

63 **Interpretation**

64 COVID-19 infection during the first trimester of pregnancy does not appear to predispose to abortion; its cumulative  
65 incidence did not differ from that of women with ongoing pregnancy.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

## 83 **Introduction**

84 The World Health Organization (WHO) named the new coronavirus (SARS-CoV-2) disease coronavirus disease-19  
85 (COVID-19) and declared it a pandemic. Coronaviruses are enveloped, non-segmented positive-sense RNA usually  
86 responsible for mild illness such as the common cold in adults and children.<sup>1</sup> But in the last decade, coronaviruses have  
87 caused two important epidemics: the severe acute respiratory syndrome (SARS) and the Middle East respiratory  
88 syndrome (MERS). COVID-19 was first reported in Wuhan (China) in December 2019 followed by outbreaks across  
89 the world.<sup>2</sup> The first cases of COVID-19 in Italy were confirmed in January 2020, with a rapid rise in the number of  
90 cases in northern Italy starting in late February.

91 Despite the rapidly growing number of cases worldwide, data on COVID-19 during pregnancy remain limited, being  
92 derived mainly from small sample studies.<sup>3-8</sup> A systematic review of published reports on coronaviruses (COVID-19,  
93 SARS, MERS) reported higher rates of preterm birth, preeclampsia, cesarean section, and perinatal death.<sup>9</sup> The lack of  
94 data on abortion due to COVID-19 during the first trimester precludes extrapolation of conclusive evidence for the  
95 effects of infection during early pregnancy. The paucity of reliable data has aroused concern in patients, while the  
96 disinformation reported by media may lead pregnant women to embrace dramatic choices such as voluntary abortion.<sup>10</sup>  
97 The wide of clinical expression, the high rate of asymptomatic forms, the poor accuracy of nasopharyngeal swab testing  
98 and its limited availability have been the main barriers to gaining a real understanding of the prevalence of the infection  
99 and its impact on pregnancy. In this complex scenario, the development of serological tests for the detection of SARS-  
100 CoV-2 IgG and IgM could be useful to identify pregnant patients who were infected during early pregnancy. While the  
101 quantity and quality of data on test performance are still limited, the level of accuracy has been reportedly  
102 moderate/good, so that patients infected by SARS-CoV-2 can be traced.<sup>11</sup>

103 The aim of the present study was to evaluate the impact of COVID-19 on first trimester spontaneous abortion by  
104 comparing the cumulative incidence of SARS-CoV-2 infection in a cohort of women who experienced early abortion  
105 and that of women with ongoing pregnancy at 12 weeks of gestational age.

## 107 **Materials and methods**

108 Women who had been referred to our Hospital for first trimester spontaneous abortion care between February 22 and  
109 May 21, 2020 were contacted and enrolled (case group). Women 12 weeks pregnant admitted to our Hospital for fetal  
110 nuchal translucency between April 16 and May 21, 2020 were the control group. The first reported case of COVID-19  
111 infection in Piedmont was dated February 22, 2020. To exclude the possibility of COVID-19 seroconversion before  
112 pregnancy, only women with last menstruation before that date were considered eligible for inclusion (Fig. 1). This  
113 criterion allowed us to define seropositivity in the case group as a seroconversion that had occurred during pregnancy.

114 Blood tests were performed for the detection of IgG/IgM non neutralizing antibodies against SARS-CoV-2 and reverse  
115 transcriptase-polymerase chain reaction (RT-PCR) assays on nasopharyngeal swabs. Patients testing positive at least one  
116 test were also tested for the determination of specific neutralizing antibodies. Blood samples were centrifuged at 3000  
117 rpm for 5 min to separate serum and analyzed the same day of collection.

118 A rapid automated fluorescent lateral flow CE-approved immunoassay (AFIAS™ COVID-19, Boditech, Gang-won-do,  
119 Korea) was used for qualitative and semi-quantitative detection of IgG/IgM non neutralizing antibodies against the  
120 spike (S) and nucleocapsid (N) viral proteins; semi-quantitative results are expressed as the cut-off index (COI) in  
121 which a COI > 1.1 indicates a positive result. Chemiluminescence CE-approved immunoassay (CLIA) technology was  
122 used for the semi-quantitative determination of anti-S1 and anti-S2 specific IgG neutralizing antibodies to SARS-CoV-2  
123 (Liaison® SARS-CoV-2 S1/S2 IgG, Diasorin, Saluggia, Italy): the antibody concentration is expressed as arbitrary

124 units (AU/mL) and grades the results as positive when  $\geq 15$  AU/mL. Viral RNA extraction from the swab was  
125 performed on a MagNA Pure compact instrument (Roche, Mannheim, Germany) and analyzed using a RT-PCR assay  
126 (CFX-96, Bio-Rad, Milan, Italy) with the Liferiver Novel Coronavirus 2019-nCov real-time RT-PCR kit protocol,  
127 targeting genes N, E, and ORF1ab (Liferiver Bio-Tech, San Diego, CA, USA).

128 Sample size calculation was not possible because the expected prevalence of disease was unknown at the time of  
129 population enrollment and further recruitment beyond May 21 would have precluded the eligibility criterion for last  
130 menstruation.

131 Demographics, COVID-19-related symptoms, and data on exposure to possible risk factors for abortion were collected  
132 by interview. The study was approved by the Institutional Review Board of the City of Health and Science of Turin  
133 (Reference number: 00171/2020). Written, informed consent was obtained from all participants. The results for  
134 quantitative variables are expressed as the mean  $\pm$  standard deviation (SD) and qualitative categorical variables are  
135 expressed as frequency and percentages. Comparison of quantitative variables was performed using the t-test or  
136 Wilcoxon-Mann-Whitney test based on normal or not distribution, respectively. Qualitative variables were compared  
137 using the chi-square test or Fisher's exact test, as appropriate. When basic patient characteristics were present as  
138 confounding factors, regression analysis was performed to assess the relationship between COVID-19 infection and  
139 spontaneous abortion. Results are expressed as odds ratio (95% confidence interval [CI]). Statistical analyses were  
140 performed using SAS software ver. 9.4 for Windows (SAS Institute, Carey, NC, USA).

141

#### 142 **Role of funding source**

143 The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the  
144 report. The corresponding author had full access to all the data in the study and had final responsibility for the decision  
145 to submit for publication.

146

#### 147 **Results**

148 A total of 225 women at first trimester of pregnancy, attending our Institute were included in the study. One hundred  
149 women in the case group and 125 women in the control group were enrolled. The patient adherence rate was 87%  
150 (100/115) and 88% (125/142), respectively. Table 1 presents the patients' characteristics at baseline; except for age,  
151 there were no statistically significant differences in demographics or risk factors for abortion between the two groups.

152 Twenty-three of the 225 women tested for anti-SARS-CoV-2 IgG and IgM antibodies were found to be seropositive or  
153 their nasopharyngeal swab tested positive for COVID-19, yielding an overall cumulative incidence of 10.2% in the first  
154 trimester. There was no significant difference in the cumulative incidence of COVID-19 between the case patients  
155 (11/100, 11%) and the controls (12/125, 9.6%) ( $p=0.73$ ).

156 The age variable was entered into logistic regression analysis to evaluate COVID-19 infection in relation to  
157 confounders. There was no difference in the odd of being infected with SARS-CoV-2 between the two groups,  
158 indicating that COVID-19 infection was not an independent predictor of abortion (1.282, CI 0.53-3.08).

159 In the case group, 5/11 (45.4%), 3/11 (27.2%), and 1/11 (9%) were positive for SARS-CoV-2 IgG, SARS-CoV-2 IgM,  
160 or both SARS-CoV-2 IgG and IgM, respectively; RT-PCR of the nasopharyngeal swab resulted positive in 2/11 (18%)  
161 (Table 2). In the control group, 7/12 (58.3%), 3/12 (25%), and 2/12 (16.6%) were positive for SARS-CoV-2 IgG,  
162 SARS-CoV-2 IgM, or both SARS-CoV-2 IgG and IgM, respectively; RT-PCR of the nasopharyngeal swab resulted  
163 positive in 5/12 (41.7%) (Table 3). No difference in positivity for IgG neutralizing antibodies was found between the  
164 case (6/11, 54.5%) and the control group (5/12, 41.7%) ( $p=0.53$ ) (Table 1). There was no statistically significant

165 difference between the two groups for average antibody titer, both non neutralizing (21.3 vs. 18.3 COI;  $p=0.42$ ) and  
166 neutralizing antibodies (39.9 vs 46.9 AU/ml;  $p=0.69$ ).

167 Twelve of the COVID-19 patients reported previous symptoms (12/23, 52.2%) including fever (7/12, 58.3%), anosmia  
168 and ageusia (5/12, 41.7%), cough (5/12, 41.7%), arthralgia (4/12, 33.3%), and diarrhea (1/12, 8.3%); no pneumonia or  
169 Hospital admission due to COVID-19-related symptoms was recorded. No difference in the incidence of symptoms was  
170 noted between the case (4/11, 36.4%) and the control group (8/12, 66.6%) ( $p=0.14$ ).

171

## 172 **Discussion**

173 With this case-control study, we evaluated the impact of COVID-19 on first trimester spontaneous abortion in a cohort  
174 of pregnant women with SARS-CoV-2 infection confirmed by antibody testing or RT-PCR assay of nasopharyngeal  
175 swabs. The results show that the risk of first trimester abortion is not impacted by SARS-CoV-2 infection, also after  
176 being adjusted for age. To the best of our knowledge, this may be the largest cohort of Coronaviruses infection during  
177 early pregnancy published so far.

178 The course of COVID-19 varies widely: patients may remain asymptomatic or develop mild to severe symptoms  
179 leading to pneumonia, respiratory failure, and death.<sup>12</sup> The non-negligible prevalence of infection in asymptomatic  
180 pregnant women reported elsewhere<sup>8,13</sup> makes universal screening of all pregnant patients appear desirable. However,  
181 because international guidelines diverge on this issue, it is difficult to determine the real impact that COVID-19 could  
182 have on pregnancy, especially during the first weeks of gestation, which are usually managed with outpatient  
183 monitoring; in some cases, abortion may be considered even before an obstetric exam has been made.

184 Serologic tests, in conjunction with SARS-CoV-2 RT-PCR assay, may offer a more feasible opportunity to identify  
185 both active and past infections and to evaluate the real spread of SARS-CoV-2, to the point that some governments have  
186 suggested their use in large-scale population tracking.<sup>14</sup> Determination of seroconversion in pregnant women could  
187 answer some concerns about unfavorable pregnancy outcomes, which are not otherwise resolvable.

188 One of the strengths of the present study is the enrollment of women with serologically confirmed COVID-19 by means  
189 of two different serological assays; the combined results of RT-PCR on nasopharyngeal swab samples is another major  
190 strength of the study. The high adherence rate to the study protocol limited confounding factors such as population  
191 selection bias. Antibodies to COVID-19 were detected in about one out of ten pregnant patients in the cohort; this  
192 finding should be carefully interpreted, however, as it cannot be generalized because derived from a single center  
193 located in a region with a high incidence of COVID-19.

194 A major limitation of the study is that we were unable to accurately backdate the time of infection in women with  
195 spontaneous abortion. In the absence of an IgG avidity test, we evaluated the time elapsed between the abortion and the  
196 blood test for antibody detection. The profile of antibodies against SARS-CoV-2 in this cohort was comparable with  
197 previous findings. Seroconversion of IgG or IgM within 20 days after symptom onset has recently been reported.<sup>15</sup> The  
198 median day of seroconversion for both IgG and IgM was 13 days with a synchronous or a discordant pattern. In light of  
199 this evidence, seroconversion during pregnancy could be excluded (or be controversial) only in one patient (no. 4, Fig.  
200 2) in the case group. The detection of IgM antibodies at 66 days after abortion does not preclude that seroconversion  
201 might have occurred after the loss of pregnancy.

202 In view of future research addressing the issue on the relationship between COVID-19 and spontaneous abortion, it will  
203 be difficult for researchers to precisely define the timing of infection and the effective seroconversion during pregnancy.

204 Inclusion criteria, together with the beginning of the study at pandemic outbreak, allowed us to fairly overcome this  
205 issue.

206 Concern is mounting about the impact of COVID-19 on pregnancy, possible vertical transmission,<sup>16-18</sup> and unfavorable  
207 obstetric outcomes in particular. Reproductive medicine societies advised delaying the start of assisted reproductive  
208 treatments<sup>19</sup> and guidelines on the prevention and control of COVID-19 among pregnant women have been issued.<sup>20-22</sup>  
209 Currently, data on the impact of Coronaviruses on the first trimester of pregnancy are limited. Four of the seven patients  
210 who presented with SARS-CoV-1 infection during their first trimester had a spontaneous abortion, likely the result of  
211 the hypoxia caused by SARS-CoV-1-related acute respiratory distress.<sup>23</sup> Furthermore, one case of a woman with MERS  
212 during the first trimester has been reported. She was asymptomatic and went on to have a term delivery.<sup>24</sup> As for SARS-  
213 CoV-2, a single abortion during the second trimester of pregnancy in a woman with COVID-19 was probably related to  
214 placental infection.<sup>25</sup> Another study reported the first visualization by electron microscopy of the SARS-CoV-2  
215 invading syncytiotrophoblasts in the placental villi.<sup>26</sup> This evidence could suggest a potential impact of SARS-CoV-2  
216 on spontaneous abortion. However, our study findings may reduce concerns in patients during the first trimester of  
217 pregnancy. In the present cohort of women who experienced an abortion during the first trimester the serological  
218 prevalence of antibodies was similar to that in the women with ongoing pregnancies. Furthermore, although viral  
219 infection at this stage could potentially affect embryogenesis and organ development, there is still no evidence for the  
220 intrauterine transmission of SARS-CoV-2.

221 Despite these reassuring data, pregnancies in women with COVID-19 can still have an unfavorable obstetric outcome:  
222 inflammatory involvement of the placenta<sup>27</sup> can be associated with preterm delivery.<sup>28</sup> Moreover, physiologic maternal  
223 adaptations to pregnancy predispose pregnant women to a more severe course of pneumonia, with subsequent higher  
224 maternal and fetal morbidity and mortality.<sup>29</sup> In this cohort, however, few patients were symptomatic and not more  
225 numerous in the case group. Severe disease was never observed. The lower incidence of severe manifestations during  
226 the first trimester could be explained by the minimal alteration in respiratory dynamics during this phase of pregnancy.  
227 In conclusion, our study provides reassuring findings for women who intend to become pregnant during the SARS-  
228 CoV-2 pandemic or who became infected during their first trimester of pregnancy. COVID-19 appears to have a  
229 favorable maternal course at the beginning of pregnancy, consistent with what has been observed during the third  
230 trimester when the clinical characteristics of COVID-19-positive pregnant women were similar to those found in  
231 women from the general population.<sup>30</sup> More importantly, no significant difference in the early abortion rate was  
232 observed. Long-term follow-up of ongoing pregnancies will respond to other doubts about the impact of COVID-19 in  
233 pregnant patients.

234

#### 235 **Authors' contributions**

236 S.C. and A.C. had roles in the study design, data interpretation, literature search, and writing the article. J.C, V.G., A.  
237 D., had roles in experiments, and data collection. C.F. had roles in the data analysis and interpretation of the data. F.B.,  
238 M. C. and M. B. had roles in recruitment, data collection, and execution of the study. G. DP. and C.B. contribute to  
239 coordinate the study. All authors reviewed and approved the final version of the manuscript.

240

#### 241 **Declaration of interest**

242 The authors report no conflict of interest

243

#### 244 **Acknowledgments**

245 We thank the staff of the Laboratory of S. Anna Hospital for sample collection and storage.

246



247 **REFERENCES**

- 248 1 Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* 2015;  
249 **1282**: 1–23.
- 250 2 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*  
251 2020; **382**: 727–33.
- 252 3 Yan J, Guo J, Fan C, *et al.* Coronavirus disease 2019 in pregnant women: a report based on 116 cases. *Am J Obstet*  
253 *Gynecol* 2020; published online April 23. DOI:10.1016/j.ajog.2020.04.014.
- 254 4 Cao D, Yin H, Chen J, *et al.* Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A  
255 retrospective study. *Int J Infect Dis* 2020; **95**: 294–300.
- 256 5 Ferrazzi E, Frigerio L, Savasi V, *et al.* Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy:  
257 a retrospective analysis. *BJOG* 2020; published online April 27. DOI:10.1111/1471-0528.16278.
- 258 6 Liao J, He X, Gong Q, Yang L, Zhou C, Li J. Analysis of vaginal delivery outcomes among pregnant women in  
259 Wuhan, China during the COVID-19 pandemic. *Int J Gynaecol Obstet* 2020; published online April 29.  
260 DOI:10.1002/ijgo.13188.
- 261 7 Breslin N, Baptiste C, Gyamfi-Bannerman C, *et al.* COVID-19 infection among asymptomatic and symptomatic  
262 pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City Hospitals. *American*  
263 *Journal of Obstetrics & Gynecology MFM* 2020; : 100118.
- 264 8 Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for  
265 Delivery. *New England Journal of Medicine* 2020; **0**: null.
- 266 9 Di Mascio D, Khalil A, Saccone G, *et al.* Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -  
267 19) during pregnancy: a systematic review and meta-analysis. *American Journal of Obstetrics & Gynecology MFM*  
268 2020; : 100107.
- 269 10 Wu Y-T, Li C, Zhang C-J, Huang H-F. Is termination of early pregnancy indicated in women with COVID-19?  
270 *European Journal of Obstetrics and Gynecology and Reproductive Biology* 2020; **0**.  
271 DOI:10.1016/j.ejogrb.2020.05.037.
- 272 11 Tré-Hardy M, Wilmet A, Beukinga I, Dogné J-M, Douxfils J, Blairon L. Validation of a chemiluminescent assay for  
273 specific SARS-CoV-2 antibody. *Clin Chem Lab Med* 2020; published online May 25. DOI:10.1515/cclm-2020-  
274 0594.
- 275 12 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in  
276 Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
- 277 13 Vintzileos WS, Muscat J, Hoffmann E, *et al.* Screening all pregnant women admitted to labor and delivery for the  
278 virus responsible for coronavirus disease 2019. *American Journal of Obstetrics & Gynecology* 2020; **0**.  
279 DOI:10.1016/j.ajog.2020.04.024.
- 280 14 Zullo F, Di Mascio D, Saccone G. COVID-19 Antibody Testing in Pregnancy. *Am J Obstet Gynecol MFM* 2020; :  
281 100142.
- 282 15 Long Q-X, Liu B-Z, Deng H-J, *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature*  
283 *Medicine* 2020; : 1–4.
- 284 16 Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and  
285 Possible Vertical Transmission. *Am J Perinatol* 2020; published online April 18. DOI:10.1055/s-0040-1710050.

- 286 17 Carosso A, Cosma S, Borella F, *et al.* Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 patients: is it time to  
287 think about it? *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2020; published online  
288 April 14. DOI:10.1016/j.ejogrb.2020.04.023.
- 289 18 Dong L, Tian J, He S, *et al.* Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her  
290 Newborn. *JAMA* 2020; published online March 26. DOI:10.1001/jama.2020.4621.
- 291 19 Vaiarelli A, Bulletti C, Cimadomo D, *et al.* COVID-19 and ART: the view of the Italian Society of Fertility and  
292 Sterility and Reproductive Medicine. *Reprod Biomed Online* 2020; published online April 8.  
293 DOI:10.1016/j.rbmo.2020.04.003.
- 294 20 Poon LC, Yang H, Kapur A, *et al.* Global interim guidance on coronavirus disease 2019 (COVID-19) during  
295 pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. *International*  
296 *Journal of Gynecology & Obstetrics* 2020; **149**: 273–86.
- 297 21 Carosso A, Cosma S, Serafini P, Benedetto C, Mahmood T. How to reduce the potential risk of vertical transmission  
298 of SARS-CoV-2 during vaginal delivery? *European Journal of Obstetrics and Gynecology and Reproductive*  
299 *Biology* 2020; **0**. DOI:10.1016/j.ejogrb.2020.04.065.
- 300 22 Rasmussen SA, Smulian JC, Lednický JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and  
301 Pregnancy: What obstetricians need to know. *Am J Obstet Gynecol* 2020; published online Feb 24.  
302 DOI:10.1016/j.ajog.2020.02.017.
- 303 23 Wong SF, Chow KM, Leung TN, *et al.* Pregnancy and perinatal outcomes of women with severe acute respiratory  
304 syndrome. *Am J Obstet Gynecol* 2004; **191**: 292–7.
- 305 24 Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection  
306 during pregnancy: Report of two cases & review of the literature. *J Microbiol Immunol Infect* 2019; **52**: 501–3.
- 307 25 Baud D, Greub G, Favre G, *et al.* Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection.  
308 *JAMA* 2020; published online April 30. DOI:10.1001/jama.2020.7233.
- 309 26 Algarroba GN, Rekawek P, Vahanian SA, *et al.* Visualization of SARS-CoV-2 virus invading the human placenta  
310 using electron microscopy. *Am J Obstet Gynecol* 2020; published online May 13. DOI:10.1016/j.ajog.2020.05.023.
- 311 27 Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology in COVID-19. *Am J Clin*  
312 *Pathol* DOI:10.1093/ajcp/aqaa089.
- 313 28 Muhidin S, Behboodi Moghadam Z, Vizheh M. Analysis of Maternal Coronavirus Infections and Neonates Born to  
314 Mothers with 2019-nCoV; a Systematic Review. *Arch Acad Emerg Med* 2020; **8**: e49.
- 315 29 Poon LC, Yang H, Lee JCS, *et al.* ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy  
316 and puerperium: information for healthcare professionals. *Ultrasound Obstet Gynecol* 2020; **55**: 700–8.
- 317 30 Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review. *J*  
318 *Matern Fetal Neonatal Med* 2020; : 1–4.

319  
320  
321  
322  
323  
324  
325  
326



327 **Table 1. Baseline characteristics, clinical findings, and COVID-19 cumulative incidence in case and control**  
 328 **groups**  
 329

Clinical findings		Case N=100	Control N=125	p-value
		No. (%) or mean ( $\pm$ SD)	No. (%) or mean ( $\pm$ SD)	
Age		35.5 ( $\pm$ 4.7)	33.7 ( $\pm$ 4.7)	0.001
BMI prior to pregnancy, Kg/m <sup>2</sup>		25.5 ( $\pm$ 4.3)	22.6 ( $\pm$ 4.1)	0.11
Pregnancy	0	51 (51)	77 (61.6)	0.34
	1	40 (40)	37 (29.6)	
	2	7 (7)	9 (7.2)	
	3	1 (1)	2 (1.6)	
	5	1 (1)	0 (0)	
Previous abortion	0	66 (66)	94 (75.2)	0.11
	1	27 (27)	21 (16.8)	
	2	6 (6)	7 (5.6)	
	3	0 (0)	3 (2.4)	
	6	1 (1)	0 (0)	
ART therapy		7(7)	12(9.6)	0.48
Smoking history		22 (22)	16 (12.8)	0.06
Thyroid disease		10 (10)	11 (8.8)	0.75
Autoimmune diseases		8 (8)	4 (3.2)	0.11
Thrombophilia		5 (5)	5 (4)	0.75
Uncontrolled DM		0	0	>0.99
Uterine abnormalities		8 (8)	9 (7.2)	0.82
COVID-19 disease		11 (11)	12 (9.6)	0.73

330 Ab, antibodies; ART, assisted reproductive technique; DM, diabetes mellitus

331

332

333

334 **Table 2. Antibody levels and SARS-Cov-2 detection in sera and nasopharyngeal swab samples from patients with**  
 335 **abortion**  
 336

Diagnostic Test	Positive result	Patient										
		1	2	3	4	5	6	7	8	9	10	11
Anti-NP IgM	COI>1.1	<1.1	2.11	<1.1	1.9	<1.1	<1.1	<1.1	<1.1	2.6	<1.1	2.9
Anti-NP IgG	COI>1.1	<1.1	18.9	<1.1	<1.1	19.4	<1.1	14.4	32.4	<1.1	21.7	<1.1
Anti-RBD IgG	$\geq$ 15 AU/ml	<15	19.5	<15	<15	29.9	49.3	17.3	41	<15	82.9	<15
NS		pos	Neg	pos	neg	neg	neg	neg	neg	neg	neg	neg

337 NS, nasopharyngeal swab; NP, nucleoprotein; RBD, receptor-binding domain

338

339

340

341 **Table 3. Antibody levels and SARS-CoV-2 detection in sera and nasopharyngeal swab samples from pregnant**  
 342 **patients.**  
 343


Diagnostic Test	Positive result	Patient											
		1	2	3	4	5	6	7	8	9	10	11	12
Anti-NP IgM	COI>1.1	<1.1	<1.1	<1.1	2.1	1.6	1.2	1.2	<1.1	1.2	<1.1	<1.1	<1.1
Anti-NP IgG	COI>1.1	19.3	19.3	15.6	<1.1	<1.1	21	<1.1	21.5	23.2	21.9	2.45	20.7
Anti-RBD IgG	$\geq$ 15 AU/ml	<15	<15	<15	<15	<15	52.7	<15	21.1	103	30.5	<15	27.5
NS		neg	pos	neg	neg	neg	pos	neg	pos	neg	pos	neg	pos

344 NS, nasopharyngeal swab; NP, nucleoprotein; RBD, receptor-binding domain

345

346

347 **Figure 1: Inclusion criteria and time of serological and molecular sampling in the case and the control group.**




348  
 349 Blue line: time range for last menstruation inclusion; dotted red line: first reported case of COVID-19 in Piedmont,  
 350 Italy; red line: time of sera and nasopharyngeal swab sample collection



351 COVID-19 outbreak cases in Piedmont Region: weekly case increase

352  
 353 **Figure 2: Patients with first trimester abortion: time elapsed between abortion care and diagnostic testing and**  
 354 **seromolecular profiles.**



355  
 356 Black arrow: last menstruation; black vertical line: abortion Hospital care; dotted black line: first reported case of  
 357 COVID-19 in Piedmont; NS: nasopharyngeal swab; rectangular green box: time elapsed between the abortion and  
 358 diagnostic testing; rectangular violet box: pregnancy; red line: serological and/or molecular sampling; x: reported  
 359 COVID-19-related symptoms; \* days elapsed between the abortion and diagnostic testing



360 COVID-19 outbreak cases in Piedmont Region: weekly case increase